SCHEMBL1411286

SCHEMBL1411286

CCCCCCCCCCCCCCCCOC(C)CC(C)C

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 1/20 0.47
LPAR3 Q9UBY5 5/20 0.40
LPAR1 Q92633 4/20 0.40
CA1 P00915 8/20 0.39
CA2 P00918 8/20 0.39
CA9 Q16790 7/20 0.39
CA12 O43570 3/20 0.39
CA7 P43166 3/20 0.39
CA14 Q9ULX7 3/20 0.39
LPAR2 Q9HBW0 2/20 0.39
CA3 P07451 2/20 0.39
CA4 P22748 2/20 0.39
CA6 P23280 2/20 0.39
CA5A P35218 2/20 0.39
CA5B Q9Y2D0 2/20 0.39
NAAA Q02083 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2330968 1.00 DNM1 (0.47) DNM1LPAR3LPAR1CA1CA2
SCHEMBL1883777 1.00 DNM1 (0.47) DNM1LPAR3LPAR1CA1CA2
SCHEMBL1411254 1.00 DNM1 (0.47) DNM1LPAR3LPAR1CA1CA2
SCHEMBL18959857 0.91 CYP3A4 (0.37) DNM1CA1CA2
SCHEMBL5163855 0.88 ALDH1A1 (0.32) DNM1
Triethylene Glycol SCHEMBL7770640 0.86 MEN1 (0.61) DNM1LPAR3LPAR1
SCHEMBL497154 0.82 DNM1 (0.42) DNM1LPAR3LPAR1CA1CA2
SCHEMBL8605070 0.82 LMNA (0.39)
SCHEMBL8542544 0.82 DNM1 (0.47) DNM1LPAR3LPAR1CA1CA2
SCHEMBL25544295 0.82 DNM1 (0.47) DNM1LPAR3LPAR1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 274 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113226032-B Pest repellent composition 花王株式会社 2023-01-03 CN claimed
CN-113226031-B Pest repellent composition 花王株式会社 2022-11-29 CN claimed
US-9943709-B2 Skin cleansing composition KAO CORPORATION (JP) 2018-04-17 US claimed
EP-2589693-B1 NANOFIBER KAO CORP (JP) 2017-10-04 EP claimed
US-20160101036-A1 SKIN CLEANSING COMPOSITION KAO CORPORATION (JP) 2016-04-14 US claimed
US-9180085-B2 Inverse latices based on fatty alcohol ethers, and cosmetic, dermocosmetic, dermopharmaceutical or pharmaceutical compositions comprising SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC (FR) 2015-11-10 US claimed
EP-2293771-B1 NOVEL INVERSE LATICES THAT ARE FREE OF OXYETHYLENE DERIVATIVES, AND COSMETIC, DERMOCOSMETIC, DERMOPHARMACEUTICAL OR PHARMACEUTICAL COMPOSITIONS COMPRISING SAME SOCIÉTÉ D EXPL DE PRODUITS POUR LES IND CHIMIQUES SEPPIC (FR) 2014-12-03 EP claimed
EP-2293770-B1 NOVEL INVERSE LATICES BASED ON FATTY ALCOHOL ETHERS, AND COSMETIC, DERMOCOSMETIC, DERMOPHARMACEUTICAL OR PHARMACEUTICAL COMPOSITIONS COMPRISING SAME SOCIÉTÉ D EXPL DE PRODUITS POUR LES IND CHIMIQUES SEPPIC (FR) 2014-08-06 EP claimed
US-20130125912-A1 NANOFIBER KAO CORPORATION (JP) 2013-05-23 US claimed
CN-102076324-B Novel inverse latices that are free of oxyethylene derivatives, and cosmetic, dermocosmetic, dermopharmaceutical or pharmaceutical compositions comprising same SEPPIC SA 2013-04-17 CN claimed
CN-102076323-B Novel inverse latices based on fatty alcohol ethers, and cosmetic, dermocosmetic, dermopharmaceutical or pharmaceutical compositions comprising same SEPPIC SA 2013-04-17 CN claimed
US-20110098364-A1 NOVEL INVERSE LATICES BASED ON FATTY ALCOHOL ETHERS, AND COSMETIC, DERMOCOSMETIC, DERMOPHARMACEUTICAL OR PHARMACEUTICAL COMPOSITIONS COMPRISING SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC (FR) 2011-04-28 US claimed
US-20110076245-A1 NOVEL INVERSE LATICES THAT ARE FREE OF OXYETHYLENE DERIVATIVES, AND COSMETIC, DERMOCOSMETIC, DERMOPHARMACEUTICAL OR PHARMACEUTICAL COMPOSITIONS COMPRISING SAME Societe D"exploitation De Produits Pour Les Industries Chimiques Seppic (FR) 2011-03-31 US claimed
EP-2293770-A2 NOVEL INVERSE LATICES BASED ON FATTY ALCOHOL ETHERS, AND COSMETIC, DERMOCOSMETIC, DERMOPHARMACEUTICAL OR PHARMACEUTICAL COMPOSITIONS COMPRISING SAME Société d'Exploitation de Produits pour les Industries Chimiques SEPPIC (FR) 2011-03-16 EP claimed
EP-2293771-A2 NOVEL INVERSE LATICES THAT ARE FREE OF OXYETHYLENE DERIVATIVES, AND COSMETIC, DERMOCOSMETIC, DERMOPHARMACEUTICAL OR PHARMACEUTICAL COMPOSITIONS COMPRISING SAME Société d'Exploitation de Produits pour les Industries Chimiques SEPPIC (FR) 2011-03-16 EP claimed
WO-2009156691-A2 NOVEL INVERSE LATICES THAT ARE FREE OF OXYETHYLENE DERIVATIVES, AND COSMETIC, DERMOCOSMETIC, DERMOPHARMACEUTICAL OR PHARMACEUTICAL COMPOSITIONS COMPRISING SAME Société d'Exploitation de Produits pour les Industries Chimiques SEPPIC (FR) 2009-12-30 WO claimed
WO-2009156690-A2 NOVEL INVERSE LATICES BASED ON FATTY ALCOHOL ETHERS, AND COSMETIC, DERMOCOSMETIC, DERMOPHARMACEUTICAL OR PHARMACEUTICAL COMPOSITIONS COMPRISING SAME Société d'Exploitation de Produits pour les Industries Chimiques SEPPIC (FR) 2009-12-30 WO claimed
US-20260144731-A1 AQUEOUS GEL, COSMETIC USE THEREOF AND PROCESS FOR REDUCING THE TACKINESS FELT DURING ITS APPLICATION SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC (FR) 2026-05-28 US disclosed
EP-0753500-A2 Process for producing ether compound KAO CORPORATION (JP) 1997-01-15 EP disclosed
WO-1996036583-A1 NOVEL ETHER COMPOUND AND PROCESS FOR PRODUCING THE SAME KAO CORPORATION (JP) 1996-11-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260144731-A1 AQUEOUS GEL, COSMETIC USE THEREOF AND PROCESS FOR REDUCING THE TACKINESS FELT DURING ITS APPLICATION OGG1, CUTA, ACP1 DNM1 4022/4885LPAR3 712/4885LPAR1 455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.